focus -WSS

focus

author：focus 2025-09-29 10:31:29 - browse：5238

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Astellas still sees hope in its gene therapy after four deaths

WSS

PBM reforms clear House panel

Pfizer's RSV vaccine recommended for approval in Europe

Ransomware attacks on hospitals: Study outlines patient impact

U.K. considers world's first use of meningitis vaccine to address gonorrhea

A former Republican legislative candidate has been charged for his role in the US Capitol riot

What is artificial intelligence? Experts weigh in

entertainment

focus

knowledge

Virginia high school admissions case could be legal follow

New chart reveals military’s vast involvement in Operation Warp Speed

New air purifier tech could be key to improving indoor air quality

Hey, doctors: Don't be no

Novavax promises a turnaround & Lilly roils the obesity market

Anthos stroke drug appears safer than common blood thinner

Medicare details structure of new drug price negotiation program

Why the advice to take all your antibiotics may be wrong

Cancer drug shortages should be causing more outrage

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

hotspot

Childhood cancer progress stalls for Black, Hispanic kids: Report

Does good food count as health care? Study aims to find out

Gain of function research would be limited under House proposal

Weight loss drug costs may need more research, senator suggests

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Congress must reauthorize a committee to support older Americans

explore

hotspot

hotspot

hotspot